alendronate has been researched along with Esophagitis in 42 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 8.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 8.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "Upper gastrointestinal tract mucosal irritations, such as esophagitis, have been reported as rare adverse events due to a variety of aminobisphosphonates, including alendronate sodium, which have been widely used to treat osteoporosis." | 7.74 | Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. ( Banno, S; Hayami, Y; Ito, R; Maeda, T; Mizoshita, T; Naniwa, T; Watanabe, M, 2008) |
| "Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis." | 7.70 | Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. ( Kelsey, P; Mueller, PR; Ryan, BM; Ryan, JM, 1998) |
| "Esophagitis is one of the adverse effects (AE) associated to its use." | 5.31 | [Esophagitis associated with use of alendronate in 5 postmenopausic patients]. ( Fay, M; Luciani, J; Naves, A; Pedrana, R; Pigatto, V; Piola, JC; Prada, DB; Silvestre Begnis, M, 2001) |
| " Soon after the release of alendronate, esophagitis and esophageal strictures were encountered, resulting in labeling changes." | 4.81 | What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. ( Graham, DY, 2002) |
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 4.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 4.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "Upper gastrointestinal tract mucosal irritations, such as esophagitis, have been reported as rare adverse events due to a variety of aminobisphosphonates, including alendronate sodium, which have been widely used to treat osteoporosis." | 3.74 | Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. ( Banno, S; Hayami, Y; Ito, R; Maeda, T; Mizoshita, T; Naniwa, T; Watanabe, M, 2008) |
| "A 6-year-old East Indian boy with asthma was mistakenly given alendronate, a bisphosphonate, for 3 months instead of montelukast, a leukotriene-receptor antagonist." | 3.72 | Dispensing error leading to alendronate ingestion. ( Bailey, B; Carrière, B; Chabot, G; Lebel, D, 2003) |
| "Alendronate sodium, an aminobiphosphonate used primarily to treat osteoporosis in postmenopausal women, is known to cause esophagitis." | 3.70 | Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features. ( Kelsey, P; Mueller, PR; Ryan, BM; Ryan, JM, 1998) |
| "Alendronate is indicated for the treatment of osteoporosis in post-menopausal women." | 3.70 | United Kingdom experience with alendronate and oesophageal reactions. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1998) |
| "Ingestion of alendronate sodium (Fosamax) by osteoporotic patients can be associated with esophagitis and esophageal ulcer." | 3.70 | Alendronate-associated esophageal injury: pathologic and endoscopic features. ( Abraham, SC; Cruz-Correa, M; Lee, LA; Wu, TT; Yardley, JH, 1999) |
| "Drug-induced esophagitis is being recognized increasingly in the past few years." | 2.45 | Drug-induced esophagitis. ( Digalakis, M; Georgiadou, D; Kaltsas, G; Thomas, D; Zografos, GN, 2009) |
| "Pill esophagitis is a rare clinical diagnosis." | 1.33 | Pill esophagitis. ( Cãtinean, A; Chira, R; Mircea, PA; Petrescu, M; Vãlean, S, 2005) |
| " At least 12 (n = 12) dosage units were tested for each product (except Fosmin, n = 10)." | 1.32 | Disintegration/dissolution profiles of copies of Fosamax (alendronate). ( Chow, J; Cryer, B; Epstein, S; Johnson, MA; Leyes, AE; Ragi, S; Walliser, J; Zanchetta, JR, 2003) |
| "Esophagitis is one of the adverse effects (AE) associated to its use." | 1.31 | [Esophagitis associated with use of alendronate in 5 postmenopausic patients]. ( Fay, M; Luciani, J; Naves, A; Pedrana, R; Pigatto, V; Piola, JC; Prada, DB; Silvestre Begnis, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (57.14) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 1 (2.38) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zabalza San Martín, L | 1 |
| Saldaña Dueñas, C | 1 |
| Gómez Alonso, M | 1 |
| Aisa Ribera, G | 1 |
| Naniwa, T | 1 |
| Maeda, T | 1 |
| Mizoshita, T | 1 |
| Hayami, Y | 1 |
| Watanabe, M | 1 |
| Banno, S | 1 |
| Ito, R | 1 |
| Shaheen, NJ | 1 |
| Zografos, GN | 1 |
| Georgiadou, D | 1 |
| Thomas, D | 1 |
| Kaltsas, G | 1 |
| Digalakis, M | 1 |
| Aibar Arregui, MA | 1 |
| de Escalante Yangüela, B | 1 |
| Muñoz Villalengua, M | 1 |
| Garcés Horna, V | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Graham, DY | 1 |
| Carrière, B | 1 |
| Bailey, B | 1 |
| Chabot, G | 1 |
| Lebel, D | 1 |
| Epstein, S | 1 |
| Cryer, B | 1 |
| Ragi, S | 1 |
| Zanchetta, JR | 1 |
| Walliser, J | 1 |
| Chow, J | 1 |
| Johnson, MA | 1 |
| Leyes, AE | 1 |
| Sia, KK | 1 |
| Iser, D | 1 |
| Heng, R | 1 |
| Chen, RY | 1 |
| Vãlean, S | 1 |
| Petrescu, M | 1 |
| Cãtinean, A | 1 |
| Chira, R | 1 |
| Mircea, PA | 1 |
| Parfitt, JR | 1 |
| Driman, DK | 1 |
| Dicko, A | 1 |
| Toulemonde, A | 1 |
| Hoareau, F | 1 |
| Avenel-Audran, M | 1 |
| Verret, JL | 1 |
| Shakweh, M | 1 |
| Bravo-Osuna, I | 1 |
| Ponchel, G | 1 |
| Maconi, G | 1 |
| Bianchi Porro, G | 1 |
| Abdelmalek, MF | 1 |
| Douglas, DD | 1 |
| de Groen, PC | 1 |
| Lubbe, DF | 1 |
| Hirsch, LJ | 2 |
| Daifotis, A | 1 |
| Stephenson, W | 1 |
| Freedholm, D | 1 |
| Pryor-Tillotson, S | 1 |
| Seleznick, MJ | 1 |
| Pinkas, H | 1 |
| Wang, KK | 1 |
| Castell, DO | 1 |
| Liberman, UI | 1 |
| Naylor, G | 1 |
| Davies, MH | 1 |
| Rimmer, DE | 1 |
| Rawls, DE | 1 |
| Pizzani, E | 1 |
| Valenzuela, G | 1 |
| Girelli, CM | 1 |
| Reguzzoni, G | 1 |
| Rocca, F | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Weihrauch, TR | 1 |
| Cameron, RB | 1 |
| Ryan, JM | 1 |
| Kelsey, P | 1 |
| Ryan, BM | 1 |
| Mueller, PR | 1 |
| Tursi, A | 1 |
| Cuoco, L | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| De Vitis, I | 1 |
| Fedeli, G | 1 |
| Gasbarrini, G | 1 |
| Chase, JL | 1 |
| Ribeiro, A | 1 |
| DeVault, KR | 1 |
| Wolfe, JT | 1 |
| Stark, ME | 1 |
| Mackay, FJ | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Tóth, E | 1 |
| Fork, FT | 1 |
| Lindelöw, K | 1 |
| Lindström, E | 1 |
| Verbaan, H | 1 |
| Veress, B | 1 |
| Larzillière, I | 1 |
| Gargot, D | 1 |
| Zleik, T | 1 |
| Ramain, JP | 1 |
| Abraham, SC | 1 |
| Cruz-Correa, M | 1 |
| Lee, LA | 1 |
| Yardley, JH | 1 |
| Wu, TT | 1 |
| Schmutz, J | 1 |
| Barbaud, A | 1 |
| Tréchot, P | 1 |
| Luciani, J | 1 |
| Pigatto, V | 1 |
| Naves, A | 1 |
| Fay, M | 1 |
| Silvestre Begnis, M | 1 |
| Piola, JC | 1 |
| Prada, DB | 1 |
| Pedrana, R | 1 |
| Larsen, KO | 1 |
| Stray, N | 1 |
| Engh, V | 1 |
| Sandnes, D | 1 |
6 reviews available for alendronate and Esophagitis
| Article | Year |
|---|---|
Drug-induced esophagitis.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Emepronium; | 2009 |
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Diphosphonates; Drug Interac | 2002 |
Pathological effects of drugs on the gastrointestinal tract: a review.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Drug-Related Side Effects | 2007 |
Esophagitis associated with the use of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Pos | 1996 |
[Alendronate-induced esophagitis. A report of 2 cases].
Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Omeprazole; Osteoporosis, Postmenopausal; Suc | 1997 |
Lowering the risk of esophagitis from alendronate therapy.
Topics: Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal | 1998 |
1 trial available for alendronate and Esophagitis
| Article | Year |
|---|---|
Esophagitis and alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Female; Humans; Osteoporosis, Postmen | 1996 |
35 other studies available for alendronate and Esophagitis
| Article | Year |
|---|---|
Oral intolerance for esophagitis secondary to alendronic acid.
Topics: Alendronate; Bone Density Conservation Agents; Esophagitis; Esophagoscopy; Female; Humans; Middle Ag | 2021 |
Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate.
Topics: Adult; Alendronate; Drug Hypersensitivity; Esophagitis; Humans; Male | 2008 |
More on reports of esophageal cancer with oral bisphosphonate use.
Topics: Alendronate; Bone Density Conservation Agents; Control Groups; Diphosphonates; Esophageal Neoplasms; | 2009 |
Esophageal stenosis caused by alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Burns, Chemical; Catheterization; Deglutition D | 2011 |
When the patient knows best.
Topics: Alendronate; Esophagitis; Female; Fractures, Bone; Hospitalization; Humans; Leg Injuries; Middle Age | 2001 |
Dispensing error leading to alendronate ingestion.
Topics: Acetates; Alendronate; Asthma; Calcium Channel Blockers; Child; Cyclopropanes; Drug Packaging; Esoph | 2003 |
Disintegration/dissolution profiles of copies of Fosamax (alendronate).
Topics: Alendronate; Biological Availability; Drugs, Generic; Esophagitis; Humans; Latin America; Osteoporos | 2003 |
Images of interest. Gastrointestinal: esophagitis caused by alendronate.
Topics: Alendronate; Esophagitis; Esophagoscopy; Female; Humans | 2004 |
Pill esophagitis.
Topics: Alendronate; Anti-Bacterial Agents; Biopsy; Doxycycline; Esophagitis; Esophagoscopy; Follow-Up Studi | 2005 |
[Mouth ulcers].
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Esophagitis; Humans; Male; Oral Ul | 2007 |
Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
Topics: Adhesiveness; Alendronate; Animals; Bone Density Conservation Agents; Dose-Response Relationship, Dr | 2007 |
Multiple ulcerative esophagitis caused by alendronate.
Topics: Alendronate; Diphosphonates; Esophagitis; Female; Humans; Middle Aged; Ulcer | 1995 |
Warning about oesophagitis with Fosamax.
Topics: Alendronate; Diphosphonates; Drug Labeling; Esophagitis; Humans | 1996 |
Alendronate-induced ulcerative esophagitis.
Topics: Aged; Alendronate; Diphosphonates; Drug Interactions; Esophagitis; Humans; Male; Ulcer | 1996 |
Postmarketing surveillance indicates need for better education of patients taking alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Humans; Patient Education as Topic; P | 1996 |
"Pill esophagitis"--the case of alendronate.
Topics: Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal; Ulcer | 1996 |
Oesophageal stricture associated with alendronic acid.
Topics: Alendronate; Esophageal Stenosis; Esophagitis; Female; Humans; Middle Aged; Osteoporosis, Postmenopa | 1996 |
Improper alendronate administration and a case of pill esophagitis.
Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Tablets | 1996 |
Esophagitis associated with alendronate sodium.
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal | 1997 |
Avoiding alendronate-related esophageal irritation.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal; Patient Education as T | 1997 |
[Drug-induced esophagitis: can stringent indications help prevent this disease picture?].
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Female; Humans; Middle Aged; Osteitis Deformans; | 1997 |
Esophagitis dissecans superficialis and alendronate: case report.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Esophageal Stenosis; Esophagitis; Esopha | 1997 |
Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture--radiographic features.
Topics: Administration, Oral; Aged; Alendronate; Dilatation; Esophageal Stenosis; Esophagitis; Female; Human | 1998 |
Ulcerative oesophagitis due to alendronate.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Ulcer | 1997 |
Alendronate-induced esophagitis.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alendronate; Canada; Esophageal Perforation; Esophage | 1998 |
Alendronate-associated esophagitis: endoscopic and pathologic features.
Topics: Adult; Aged; Alendronate; Biopsy, Needle; Esophagitis; Esophagoscopy; Female; Follow-Up Studies; Hum | 1998 |
United Kingdom experience with alendronate and oesophageal reactions.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postm | 1998 |
[Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
Topics: Aged; Alendronate; Burns, Chemical; Diphosphonates; Esophageal Stenosis; Esophagitis; Esophagoscopy; | 1998 |
Alendronic acid: new preparation. Limited efficacy, risk of oesophagitis.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Esophagitis; Female; Fractur | 1998 |
[Esophagitis associated with the use of alendronate].
Topics: Aged; Aged, 80 and over; Alendronate; Esophagitis; Esophagoscopy; Female; Humans | 1999 |
Alendronate-associated esophageal injury: pathologic and endoscopic features.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Esophagitis; Esophagoscopy; Esophagus; Fe | 1999 |
Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Ther | 2000 |
[Monosodium alendronate].
Topics: Alendronate; Esophagitis; Humans; Oral Ulcer | 2000 |
[Esophagitis associated with use of alendronate in 5 postmenopausic patients].
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenop | 2001 |
[Esophageal lesions associated with diphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Esophageal Stenosis; Esophagitis; Esophagoscopy; Esophagus; Etidr | 2000 |